Articles related to CHECKPOINT INHIBITORS

Based on prior studies in patients with melanoma and lung cancer as well as overall response and duration of response rates in open-label, multiple cohort trials involving 131 adults and 36 children, the combination was approved for the new indication (treatment of unresectable or metastatic solid tumors with a BRAF V600E mutation in patients ≥6 years old who have progressed following prior treatment and have no satisfactory alternative treatment options). Adults with BRAF V600E mutation-positive solid tumors, such as low-grade glioma (LGG), anaplastic thyroid cancer, biliary tract cancer, small intestine cancer, and high-grade glioma (HGG), were enrolled in the new trials, along with 36 children with BRAF V600 refractory or recurrent LGG or HGG. The overall response rate (ORR) served as the trial’s main measure of success, and out of the 131 adults who participated, 54 (41%) had an objective reaction. Among the most prevalent tumor types in the clinical trials, the ORR for biliary tract cancer was 46%, HGG was 33%, and LGG was 50%. Children’s ORR was 25%.

The development of new androgen receptor pathway inhibitors (ARPis) has resulted in a dramatic therapeutic paradigm change for the older adult illness of prostate cancer. Enzalutamide is one of the ARPis that is used more frequently. Darolutamide, apalutamide, and this medication were all first approved for the treatment of metastatic castrate-resistant prostate cancer, but they are now routinely used in the treatment of metastatic castrate-sensitive and non-metastatic castration-resistant prostate cancer. Only older persons with outstanding performance status are included in landmark phase III data demonstrating the effectiveness of ARPi in these patients. However, in the context of a narrative review, its function in older prostate cancer patients who are ineligible has to be investigated.

Although immune therapies, such as immune checkpoint inhibitors (ICIs), have significantly improved cancer outcomes, these therapies can also cause off-target tissue damage and response variability. The host microbiome affects ICI responsiveness and risk of immune-related adverse effects (irAEs), according to numerous lines of evidence. These developments show the possibility to control microbiome elements to improve the success of ICI because the microbiome is manipulable.

The diagnosis and treatment of mantle cell lymphoma are covered in this podcast by Jonathon Cohen, MD, MS, Associate Professor, Hematology and Medical Oncology, Emory University School of Medicine. He also discusses how BTK inhibitors and CAR T-cell therapy are changing the treatment landscape and what he expects will be presented at upcoming conferences.

Taking place February 3 – 5, 2023 at the JW Marriott Scottsdale Camelback Inn Resort & Spa in Paradise Valley, Arizona, live and virtual attendees will learn how to distinguish between immunotherapy combinations in metastatic RCC, identify actionable target therapy in the treatment of metastatic lung cancer, identify targeted therapies for CNS metastases, review management of resectable melanoma – neoadjuvant versus adjuvant immune checkpoint blockade, and assess the approved and developing categories of prostate cancer patients eligible for PSMA-targeted therapy.

Today, it is possible to safely treat CML throughout pregnancy with little danger to the unborn child, as TKIs can now be safely administered during the later stages of pregnancy, according to new research. After beginning or continuing TKI therapy, a sizable majority of patients can be managed by observation alone, and disease control can be attained. IFN-α may be given in any trimester with little harm to the fetus if active treatment is necessary. Most essential, however, is a multidisciplinary strategy to offer clear and concise guidance to enable both the mother and the family to participate in the decision-making process.